(EMAILWIRE.COM, October 24, 2019 ) The slide stainers market was valued at USD 2.52 billion in 2017 and is expected to reach USD 4.70 billion in 2023, at a CAGR of 11.0% during the forecast period.

The major factors driving the growth of Slide Stainer market include the increasing incidence of chronic diseases, rising geriatric population, growing automation in laboratories, and increasing healthcare expenditure.
The reagents segment accounted for the largest share of the global slide stainers market in 2017. The large share of this segment is attributed to the rising prevalence of chronic and infectious diseases, increasing healthcare expenditure, increasing public awareness, and growing demand for automation in diagnostics and clinical research.

Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134046412

The slide stainers market is segmented into hematoxylin and eosin (H&E), immunohistochemistry, in situ hybridization, cytology, microbiology, hematology, and special stains. In 2017, the H&E segment accounted for the largest share of the slide stainers market. The large share of this segment can be attributed to the fact that H&E staining is the initial staining technique for various diseases and is associated with better quality, ease of use, and higher throughput than most other staining technologies.

Geographically, the global slide stainers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2017, North America accounted for the largest share of the slide stainers market, followed by Europe and Asia Pacific. Factors such as the highly developed healthcare system in this region, the easy accessibility to technologically advanced instruments, and the presence of major key players in the region are responsible for the large share of the North American slide stainers market.

Request Sample Pages @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=134046412

The prominent players in the global slide stainers market are Roche (Switzerland), Agilent (US), Danaher (US), BioGenex (US), Thermo Fisher Scientific (US), Sakura (Japan), Biocare Medical (US), Merck Group (Germany), General Data Company (US), and Hardy Diagnostics (US).